Retrospective Study
Copyright ©The Author(s) 2024.
World J Gastroenterol. Nov 21, 2024; 30(43): 4620-4635
Published online Nov 21, 2024. doi: 10.3748/wjg.v30.i43.4620
Figure 5
Figure 5 Kaplan-Meier curves based on α-fetoprotein and carcinoembryonic antigen score. A: Kaplan-Meier curves based on progression-free survival (PFS); B: Kaplan-Meier curves based on overall survival (OS); C: Kaplan-Meier curves based on PFS in the bevacizumab plus sintilimab plus interventional treatment (BeSiIT) groups; D: Kaplan-Meier curves based on OS in the BeSiIT groups; E: Kaplan-Meier curves based on PFS in the lenvatinib plus sintilimab plus interventional treatment (LeSiIT) groups; F: Kaplan-Meier curves based on OS in the LeSiIT groups. AFCE: Α-fetoprotein and carcinoembryonic antigen score; PFS: Progression-free survival; OS: Overall survival.